Pharmos(PARS) | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks
Pharmos(PARS)

An SI Board Since November 1996

Posts	SubjectMarks	Bans	Symbol
1491	8	0	PARS

Emcee:	Type: Unmoderated

Introduction Market Data Compact

Nasdaq Small Caps (PARS)
Current price $1.31
52 week price range $2.875-$1.125
Shares outstanding 29,000,000
Institutions owns 16%

Pharmos is a Florida-based bio-tech company that develops topically-applied ophthalmic drugs. Pharmos has filed a New Drug Application (NDA) for its leading drug Lotemax. Lotemax is a drug that treats acute eye inflammation due to irritation and infection. The company expects the FDA to approve it by the second quarter of 97'.
Also the company also expects to file an NDA for Lotemax-LEA( a low dose formulation of Lotemax that will be use as a treatment for chronic allergic cnjuctivitis) by the first quater of 97' and expects it to get approved by 1Q of 98'. Bausch and Lomb will market both Lotemax products in the U.S. and pay Pharmos 30% of net sales. Lotemax will compete with several ophthalmic steroid, but its superior side effect profile should enable it to capture a 30% share of the $100million market in the U.S. They also have signed a letter intent with Bausch and Lomb for overseas marketing rights. The combined market for the Lotemax products is $200million.
Pharmos is also developing a drug called Dexananbinal that is intended to prevent brain damage following head trauma or stroke. It works like this. It crosses the so-called blood-brain barrier that prevents foreign molocules from entering the brain. And once in, the drug halts the brain-cell deterioration that follows a blow to the head or a stroke. They are entering a billion doller market with this drug. Currently it's in Phase II studies and could be out on the market by the year 2000.
Also, 16% of the company shares are owned by institutions which is a very good sign. Expect this stock to triple in the next 6 months.
There is a small article about there drug Dexanabinol in Business Week
11/04/96 on page 199.

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
1491	SmallCaps Online LLC Initiates Coverage on Pharmos with a BUY Release: biz.ya	BridgeTech	-	11/11/1999
1490	Pharmos and Dexanabinol featured on the national CBS Evening news on 8/1/99.	erin4	-	8/1/1999
1489	Rick, agreed. I will no longer post here. You can find me on the biotech thread	Ariella	-	10/30/1998
1488	crysball, You're absolutely right, management should be applauded for choo	Omer Shvili	-	10/30/1998
1487	Now that PARS is on the Biotech board here at SI, can't we move our discuss	Rick Strange	-	10/30/1998
1486	PARS Society for the Neurosciences abstracts Message 6212905 Message 6222005	Dr. John M. de Castro	-	10/30/1998
1485	crysball, slow down. The potential market is huge. But at the current time no	wolfdog2	-	10/30/1998
1484	I thought that HU 211 is in phase 3 I will have to check again. Tamoxiphen anal	yosi s	-	10/30/1998
1483	NBC News this morning expanded the definintion of at 'high' risk can	crysball	-	10/30/1998
1482	crysball, calm down. You are getting all worked up about a drug that hasn'	wolfdog2	-	10/29/1998
1481	Currently tamoxiphen as adjuvent therapy is taken for 5 years. As for preventio	yosi s	-	10/29/1998
1480	More on Tamoxifen From the description of the patient population at high	crysball	-	10/29/1998
1479	GOOD NEWS for PARS The FDA today approved the use of Tamoxifen to prevent bre	crysball	-	10/29/1998
1478	I spoke with company yesterday and was told eps were due out Friday, Monday or	Ariella	-	10/29/1998
1477	I just opened a Pharmos thread in the biotechnology section of SI. PARS is a bi	Dr. John M. de Castro	-	10/29/1998
1476	Can anyone provide an LE-T Update? I've been looking to get an update on th	Dr. John M. de Castro	-	10/27/1998
1475	Bought more shares today @2. I would like to thank all the contributors to this	Tony van Werkhooven	-	10/27/1998
1474	OT: David, Give me a call or email me next time you come to Israel. We'll	Omer Shvili	-	10/27/1998
1473	Rick, I do not suggest that we need to become RISKY just Prudent !!!	David Israel-Rosen	-	10/27/1998
1472	David, with all due respect, I would rather have shorts sticking around for a w	Rick Strange	-	10/27/1998
1471	Assuming that not everybody of you is familiar with German, I tried to find out	Richard Huth	-	10/27/1998
1470	Omer: I completely agree with you. My point was that given the Cautious style	David Israel-Rosen	-	10/27/1998
1469	David, Hiring a good PR/IR firm is not like using a magic wand. Once a company	Omer Shvili	-	10/27/1998
1468	Dear Yosi: Given the General Volume in the stock and MGT clear lack of intere	David Israel-Rosen	-	10/26/1998
1467	short intrest on Pharmos keeps growing. Some people just do not get it. 10/22	yosi s	-	10/26/1998

Go to reply# or date (mm/dd/yy):